Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress.

2019 年冠状病毒（COVID-19；由严重急性呼吸系统综合症冠状病毒 2 引起；SARS-CoV-2）是当前的全球健康问题。先前的研究表明，用最初作为抗癌药物开发的出口蛋白 1 (XPO1) 抑制剂阻断核质转运可以隔离宿主细胞核中的关键病毒辅助蛋白和基因组材料，并减少病毒复制和免疫致病性。这些观察结果支持将抑制核输出作为针对一系列病毒（包括甲型流感、乙型流感和 SARS-CoV）的有效策略的概念。使用 XPO1 抑制剂 selinexor 治疗 COVID-19 感染的临床研究正在进行中。